Related references
Note: Only part of the references are listed.
Article
Respiratory System
Ashley Losier et al.
CLINICS IN CHEST MEDICINE
(2023)
Article
Critical Care Medicine
Alexis Tabah et al.
Summary: This study investigated hospital-acquired bloodstream infections (HA-BSI) in 2600 adult patients from 333 ICUs in 52 countries. HA-BSI were frequently caused by Gram-negative, carbapenem-resistant, and difficult-to-treat pathogens. Antimicrobial resistance led to delays in adequate antimicrobial therapy, resulting in high mortality rates.
INTENSIVE CARE MEDICINE
(2023)
Review
Multidisciplinary Sciences
Ruhana Che Yusof et al.
Summary: This systematic review aimed to provide the pooled prevalence of bacterial coinfection in hospitalized COVID-19 patients from 2020 to 2022. The study found that the pooled prevalence of bacterial coinfection was 26.84%, with common isolated bacteria including Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus. The prevalence of antibiotic-resistant bacteria was also mentioned. These coinfections have a negative impact on patient morbidity and mortality, highlighting the importance of effective management and prevention measures.
Article
Microbiology
Stelios F. Assimakopoulos et al.
Summary: This study retrospectively evaluated the characteristics, treatment regimens, and outcomes of 20 patients with primary bacteremia caused by pan-drug resistant Acinetobacter baumannii (PDR-AB) in the ICU. The inclusion of fosfomycin in the combination therapeutic regimen was associated with significantly better survival than non-fosfomycin-containing regimens.
Review
Infectious Diseases
Marios Karvouniaris et al.
Summary: Gram-negative bacterial resistance to antimicrobials has been increasing globally in recent decades, posing a daily challenge for hospital practice. Researchers and industry have made efforts to develop novel antimicrobials resilient to bacterial resistance mechanisms. Several new antimicrobials, including cefiderocol, imipenem-cilastatin-relebactam, eravacycline, omadacycline, and plazomicin, have become commercially available in the past five years. Other agents, such as aztreonam-avibactam, cefepime-enmetazobactam, cefepime-taniborbactam, cefepime-zidebactam, sulopenem, tebipenem, and benapenem, are in advanced development and have reached phase 3 clinical trials. This review critically discusses the characteristics, pharmacokinetic/pharmacodynamic properties, and current clinical data of these antimicrobials.
Review
Infectious Diseases
Bradley J. Langford et al.
Summary: This article describes the impact of the COVID-19 pandemic on antimicrobial resistance (AMR), particularly in hospital settings for Gram-negative organisms. The study found that the absence of enhanced infection prevention and control and/or antimicrobial stewardship programs was associated with an increase in Gram-negative AMR. Therefore, strengthening infection prevention, antimicrobial stewardship, and AMR surveillance are necessary in the context of the COVID-19 pandemic.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Health Care Sciences & Services
Thamer A. Alenazi et al.
Summary: This single-center, retrospective, cohort study evaluated the clinical outcomes of multi-drug resistance in Acinetobacter baumannii infections (MDR-AB) in ICU patients with or without COVID-19 infection and risk factors for bloodstream infection. The study included 170 MDR-AB patients, of which 118 were admitted to the ICU due to COVID-19 infection. Patients with COVID-19 had higher rates of mechanical ventilation, septic shock, and the use of steroids and tocilizumab therapies. The average length of ICU stay was significantly lower in COVID-19 patients, but their survival rate was lower and COVID-19 infection was associated with higher hazards of death.
Article
Infectious Diseases
A. Russo et al.
Summary: This study observed VAP and concurrent bloodstream infections caused by CRAB, finding that chronic obstructive pulmonary disease and age were independently associated with 30-day mortality, while cefiderocol-containing regimens and cefiderocol + fosfomycin in combination were independently associated with 30-day survival.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Public, Environmental & Occupational Health
I. Gajica et al.
Summary: This study evaluated the prevalence, causes, and antibiotic resistance patterns of bacterial infections in hospitalized patients with laboratory-confirmed SARS-CoV-2. It also investigated comorbidities, risk factors, and mortality rate in COVID-19 patients with bacterial infections. The findings reveal a significant association between healthcare-associated bacterial infections as an important complication of COVID-19 and fatal outcomes.
JOURNAL OF HOSPITAL INFECTION
(2023)
Article
Critical Care Medicine
M. Elizabeth Wilcox et al.
Summary: During the COVID-19 pandemic, ICU capacity strain had an impact on the hospital mortality of patients admitted to ICUs. In the first wave, COVID-19 patients admitted during periods of high ICU capacity strain had no difference in hospital mortality, but in the second wave, there was an increased mortality rate. For non-COVID-19 patients, there was little difference in trend between the two waves, but there was an increased mortality rate in periods of high ICU capacity strain.
CRITICAL CARE MEDICINE
(2022)
Article
Critical Care Medicine
Charles-Herve Vacheron et al.
Summary: This study estimated the mortality rate of VAP in COVID-19 patients, finding that COVID-19 patients had higher attributable mortality related to VAP, with more than 9% of overall mortality attributed to VAP.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Infectious Diseases
Alessandro Russo et al.
Summary: Our study found that COVID-19 patients exhibited higher occurrences of serum lactate levels mmol/l > 2, Acinetobacter baumannii colonization, BSI, and steroid therapy. Cox regression analysis demonstrated that serum lactate levels > 2 mmol/l, Acinetobacter baumannii colonization, BSI, and steroid therapy were associated with 30-day mortality. Additionally, factors independently associated with the development of BSI in COVID-19 patients included white blood cells count > 11,000 mm(3), serum lactate levels > 2 mmol/l, infections at time of ICU admission, Acinetobacter baumannii colonization, and steroid therapy.
Article
Infectious Diseases
Diaa Alrahmany et al.
Summary: This study investigated factors contributing to mortality rates in nosocomial Acinetobacter baumannii infections, finding age, admission to critical care units, and infectious diagnosis to be significantly associated with higher mortality. Interventions such as improving multidisciplinary infection control, regular disinfection, and optimal intubation practices can reduce infection-related mortality rates.
Review
Critical Care Medicine
Aritz Perez Ruiz de Garibay et al.
Summary: Organ dysfunction or overt failure is common in critically ill patients, affecting up to 70% of patients in the ICU. Acute Liver Failure is a rare and potentially reversible severe liver injury, and dysfunction of the liver plays a critical role in Multiple Organ Dysfunction Syndrome. Conventional laboratory markers are limited in understanding liver dysfunction, and inconsistent definitions of these entities result in widely ranging estimates of incidence.
Review
Immunology
Cornelius J. Clancy et al.
Summary: Research shows that potential bacterial lung superinfections were present in 32% of patients who died with COVID-19, with most of them receiving antimicrobial treatment. The most common pathogens identified in postmortem studies included Acinetobacter baumannii, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Superinfections were rarely the direct cause of death, ranking third behind other factors.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Review
Microbiology
Karyne Rangel et al.
Summary: The COVID-19 pandemic has led to overuse of antimicrobials in critically ill patients, increasing the incidence of pathogens like Acinetobacter baumannii in ICUs. Patients with COVID-19 are at risk of secondary bacterial infections due to comorbidities and immune dysfunction.
Article
Microbiology
Georgios Papathanakos et al.
Letter
Infectious Diseases
Georgios Papathanakos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2020)
Article
Medicine, General & Internal
Hua Zhou et al.
Article
Infectious Diseases
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES
(2018)
Article
Medicine, General & Internal
Mervyn Singer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2016)
Article
Critical Care Medicine
Shelley S. Magill et al.
CRITICAL CARE MEDICINE
(2013)
Review
Critical Care Medicine
John A. Kellum et al.
